# Liposome-exosome hybrids for in situ detection of exosomal miR- 

## 1246 in breast cancer

Xuting Zhou ${ }^{\text {a, d }}$, Wenting Tang ${ }^{\text {a }}$, Yan Zhang ${ }^{\text {c }, ~ Y u e h u a ~ G u o ~}{ }^{\text {b, } \text { * }, ~ L i ~ Q i a n ~}{ }^{\text {a, } \text { * }}$<br>${ }^{\text {a }}$ Department of Oncology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226000, China. E-mail: ntqianli@163.com<br>${ }^{\mathrm{b}}$ Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226000, China. E-mail: guoyuehuanju@163.com<br>${ }^{\text {c }}$ Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, China<br>${ }^{\text {d }}$ Department of Oncology, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, 226006, China

*Corresponding author

E-mail address: guoyuehuanju@163.com (Y. Guo); ntqianli@163.com (L. Qian)

Table of contents

1. Table S1. Sequences of oligonucleotides used in this work
2. TEM images of liposome-exosome hybrids.
3. Expression of miR-1246 in MCF-7 exosomes and MCF-10A exosomes
4. Table S2. The TNM stage of patients.
5. Table S1. Sequences of oligonucleotides used in this work.

| Name | Sequence (from 5' $\mathbf{5}^{\prime} \mathbf{3}^{\prime}$ ) |
| :---: | :---: |
| crRNA | GGA CCA CCC CAA AAA UGA AGG GGA CCA AAA CCC |
|  | UCU CCA AAA UCC AUU |
| Reporter RNA | FAM-UUUUU-BHQ1 |
| Random RNA | UUG UAC UAC ACA AAA GUA CUG |
| miR-1246 | AAU GGA UUU UUG GAG CAG G |
| miR-21 | UAG CUU AUC AGA CUG AUG UUG A |
| miR-122 | UGG AGU GUG ACA AUG GUG UUU G |

2. TEM images with more liposome-exosome hybrids.


Fig. S1 TEM images with more liposome-exosome hybrids.
3. Expression of miR-1246 in MCF-7 exosomes and MCF-10A exosomes


Fig. S2. Detection of the expression of miR-1246 in MCF-7 exosomes and MCF-10A exosomes by real-time $\mathrm{q}-\mathrm{PCR}\left({ }^{* * *} \mathrm{p}<0.001\right)$.
4. Table S2. The TNM stage of patients.

| Patient | TNM stage | Clinical stage | Patient | TNM stage | Clinical stage |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | $\mathrm{~T}_{3} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 21 | $\mathrm{~T}_{1} \mathrm{~N}_{1} \mathrm{M}_{0}$ | II |
| 2 | $\mathrm{~T}_{2} \mathrm{~N}_{0} \mathrm{M}_{1}$ | IV | 22 | $\mathrm{~T}_{2} \mathrm{~N}_{0} \mathrm{M}_{0}$ | II |
| 3 | $\mathrm{~T}_{1} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 23 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV |
| 4 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 24 | $\mathrm{~T}_{3} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV |
| 5 | $\mathrm{~T}_{2} \mathrm{~N}_{1} \mathrm{M}_{1}$ | IV | 25 | $\mathrm{~T}_{2} \mathrm{~N}_{1} \mathrm{M}_{1}$ | IV |
| 6 | $\mathrm{~T}_{2} \mathrm{~N}_{0} \mathrm{M}_{1}$ | IV | 26 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV |
| 7 | $\mathrm{~T}_{1} \mathrm{~N}_{0} \mathrm{M}_{0}$ | I | 27 | $\mathrm{~T}_{3} \mathrm{~N}_{1} \mathrm{M}_{1}$ | IV |
| 8 | $\mathrm{~T}_{1} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 28 | $\mathrm{~T}_{3} \mathrm{~N}_{3} \mathrm{M}_{0}$ | III |
| 9 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 29 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV |
| 10 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 30 | $\mathrm{~T}_{2} \mathrm{~N}_{0} \mathrm{M}_{0}$ | II |
| 11 | $\mathrm{~T}_{3} \mathrm{~N}_{1} \mathrm{M}_{1}$ | IV | 31 | $\mathrm{~T}_{3} \mathrm{~N}_{1} \mathrm{M}_{0}$ | III |
| 12 | $\mathrm{~T}_{3} \mathrm{~N}_{1} \mathrm{M}_{1}$ | IV | 32 | $\mathrm{~T}_{1} \mathrm{~N}_{0} \mathrm{M}_{0}$ | I |
| 13 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{0}$ | III | 33 | $\mathrm{~T}_{2} \mathrm{~N}_{0} \mathrm{M}_{0}$ | II |
| 14 | $\mathrm{~T}_{2} \mathrm{~N}_{0} \mathrm{M}_{0}$ | II | 34 | $\mathrm{~T}_{1} \mathrm{~N}_{0} \mathrm{M}_{0}$ | I |
| 15 | $\mathrm{~T}_{1} \mathrm{~N}_{0} \mathrm{M}_{0}$ | I | 35 | $\mathrm{~T}_{2} \mathrm{~N}_{3} \mathrm{M}_{1}$ | IV |
| 16 | $\mathrm{~T}_{1} \mathrm{~N}_{1} \mathrm{M}_{0}$ | II | 36 | $\mathrm{~T}_{1} \mathrm{~N}_{0} \mathrm{M}_{0}$ | I |
| 17 | $\mathrm{~T}_{3} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 37 | $\mathrm{~T}_{2} \mathrm{~N}_{1} \mathrm{M}_{1}$ | IV |
| 18 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV | 38 | $\mathrm{~T}_{3} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV |
| 19 | $\mathrm{~T}_{4} \mathrm{~N}_{1} \mathrm{M}_{0}$ | III | 39 | $\mathrm{~T}_{2} \mathrm{~N}_{2} \mathrm{M}_{1}$ | IV |
| 20 | $\mathrm{~T}_{2} \mathrm{~N}_{1} \mathrm{M}_{1}$ | IV | 40 | $\mathrm{~T}_{1} \mathrm{~N}_{0} \mathrm{M}_{0}$ | I |

